NovoCure Limited
NVCR
$16.50
$0.422.61%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 161.27M | 155.10M | 150.36M | 138.50M | 133.78M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 161.27M | 155.10M | 150.36M | 138.50M | 133.78M |
| Cost of Revenue | 32.51M | 35.37M | 34.65M | 33.64M | 31.81M |
| Gross Profit | 128.75M | 119.72M | 115.70M | 104.87M | 101.97M |
| SG&A Expenses | 139.89M | 99.93M | 94.35M | 93.03M | 94.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 223.62M | 187.19M | 183.96M | 177.99M | 178.79M |
| Operating Income | -62.35M | -32.09M | -33.61M | -39.49M | -45.00M |
| Income Before Tax | -55.21M | -21.59M | -22.73M | -31.64M | -38.53M |
| Income Tax Expenses | 10.72M | 8.99M | 10.65M | 7.12M | 8.55M |
| Earnings from Continuing Operations | -65.92M | -30.57M | -33.38M | -38.76M | -47.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.92M | -30.57M | -33.38M | -38.76M | -47.08M |
| EBIT | -62.35M | -32.09M | -33.61M | -39.49M | -45.00M |
| EBITDA | -60.62M | -29.63M | -30.75M | -36.68M | -43.55M |
| EPS Basic | -0.61 | -0.28 | -0.31 | -0.36 | -0.44 |
| Normalized Basic EPS | -0.47 | -0.12 | -0.14 | -0.17 | -0.34 |
| EPS Diluted | -0.61 | -0.28 | -0.31 | -0.36 | -0.44 |
| Normalized Diluted EPS | -0.47 | -0.12 | -0.14 | -0.17 | -0.34 |
| Average Basic Shares Outstanding | 108.47M | 108.25M | 107.70M | 107.27M | 106.98M |
| Average Diluted Shares Outstanding | 108.47M | 108.25M | 107.70M | 107.27M | 106.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
